1 !
Wpływ stężeń terapeutycznych zyprazydonu na poziom wolnych tioli
i związków reagujących z kwasem tiobarbiturowym w osoczu – badania in vitro
The effects of therapeutic concentrations of ziprasidone on free thiols and thiobarbituric acid
reactive substances levels in human plasma – in vitro studies
D > R @ 9* * @ @ @ @ @QO9* * @
238
5
@ @ @ @ ND8>O9*^*<"2$4*;*$2$F$'@ @ NR8QO8*HG"B%$#;";G'"* @ @ H3/N=8CO @ @ NQO @ @ @ @ @ NS@EO9*^*<"2$4*;*4''.)1*BG(G'4G)1*&#";G(H"'.)1* ;*F"($2/* 'G*24'4G)1*<"FP#<";.)1*%+;4$#(H"'"8* @ @ <4ND?@D>O 'G*2/(H<4F*"%")H/*&"B#G'.F*"(*"%PB*H(#";.)1* @ @ &4'.*4*<;$+4G&4'.*;*"('4$%4$'4/*("*&#PB*<"'+#"2'.)1*[*B$H* 2$</ND8DRO @#$%&'()*%#'$
-
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
#.*%$#"+"'4'$#34)H'$*=UM>!8*=UM *4*=UMD\8*&#H.*)H.F*
@ @ > @ &";4'";G)+;"*("*#$)$&+"#P;*14%+GF4'";.)1*+.&/*UD*4*#$@ D9*0";4'";G)+;"*("*#$)$&+"#P;*F/@ %<G#.'";.)1*+.&/*6D*;*&#H.&G(</*H.&#GH.("'/*'4$*FG* 4%+"+'$3"*H'G)H$'4GNDQO @ @ ND=8DCO9*^.&#GH.("'* %+"%";G'.*("/%+'4$*&"(2$3G*&#H$F4G'"F*F$+GB"24)H'.F* @ (#"H.&#GH.("'NDSO @ > NDSO9*LG(G'4G# @ @ @ @ NDQO @ @ NDA8DEO ;4$2"<#"+'.F*("/%+'.F*&"(G'4/*H.&#GH.("'/*N&"*&"@ 4%*4F&"#+G'+*4'*)24'4)G2*G'(*)"3'4+4J$*#$%&$)+8*B$)G/%$*G'@ #$("T*&#")$%%$%9 ^4&#G%4("'$*N *[*=@`>@NQ@`D8>@B$'H4%"+14GH"2@ >@"'$O*4%*+1$*%$)"'(*3$'$#G+4"'*G'+4&%.)1"+4)*$T14B4+4'3* @
)$&+"#%*>\*N=UM>\ >O9*
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±QA9D8* DDA9C±A?9D*G'(*DRE9Q± NDEO9*7)#$$'4'3*+$%+%*(4(* @ FG)"<4'$+4)%*B$+;$$'*+"BG))"*%F"<$#%*G'(*'"'@%F"<$#%9*
240
@ @ NDQO9 @ ;*;G#/'<G)1* 9 @ @ @ @ -'+$#J4$;N>?O9*0#H$&#";G(H"'"*BG(G'4G*4'+$#'4%+.)H'$8*'$/@ @ @ @ @ @ @ @ @ @ @ @ @ @)
@ @ &$#"T4(G+4"'*F$G%/#$(*B.*+14"BG#B4+/#4)*G)4(@#$G)+4J$*%/B@ *)"'(4+4"'%9 @ G3$*>=b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
)
@ @ @ @ @ @@ @ @ @ N>DO @ N>D8>>O9
)
;*"%")H/*4'</B";G'.F*>Q*3"(H4'.*H*H.&#GH.("'$F* @ FG'G*H*;.<"#H.%+G'4$F*<;G%/*=8=K@(4+4"B4%@N>@'4+#"B$'@ ("*&";%+G'4G*BG#;'$3"*(4G'4"'/*<;G%/*=@+4"@>@'4+#"@ λ N>DO @ ε @D @DO9*5H.%<G'$*;.'4<4*&#H$(%+G@ @ @ N>RO @ <#"+'.)1*&";+P#H$'4G)19 @ @ @ ;$3"*NML\O*;*?8>=*6*U!29*0#PB.*F4$%HG'"*4*"3#H$;G'"* @ @ @ @ @ ε =*6@D @D @ +$F&$#G+/#$9*Z"#*$G)1*$T&$#4F$'+*+1$*)"'+#"2*%GF&2$%* @ +$#*4')/BG+4"'*;4+1*+1$*H4&#G%4("'$*)"')$'+#G+4"'%*;$#$* @ @ "(N>DO N>D8>>O9 @ 4'*)"'+#"2*%GF&2$%*;4+1"/+*+1$*+$%+$(*(#/38*;$#$*F$G%/#$(* @ @ λ N>DO9* M1$*+"+G2*+14"2%*)"')$'+#G+4"'*;G%*)G2)/2G+$(*BG%$(*"'* @ 4"'*Nε @D @DO9*M1$*"B+G4'$(*#$%/2+%*;$#$*$T@ @ @ B/F4'*%"2/+4"'*;G%*/%$(*G%*G*%+G'(G#(N>RO9*M1$*+14"2%*)"'@ )$'+#G+4"'*F$G%/#$F$'+%*;$#$*FG($*4'*(/&24)G+$9)
@ @ +14"BG#B4+/#4)*G)4(*NML\O*4'*?9>=*6*U!29*M1$*%GF&2$%* @ @ %/&$#'G+G'+* ;G%* F$G%/#$(* /%4'3* D* )F* +14)<* )/J$++$* G+*λ )"'+$'+*;G%*)G2)/2G+$(*BG%4'3*"'*GB%"#BG')$*JG2/$8*/%4'3* ε =*6@D @DO9* @-0%01-01,%2)%3%2$-1-@ +4%+4)G2*G'G2.%4%,*G#4+1F$+4)*F$G'%*G'(*%+G'(G#(*($J4G@
242
%3%21#%)-0%0$-0$,#3%
@ @ @ @ @ ;G%*/%$(9 G%*)"F&G#$(*+"*+1$*)"'+#"2*%GF&2$%8*)G/%$(*G*%+G+4%+4)G22.* @ FG*N>Q*1"/#%O8*G%*)"F&G#$(*+"*)"'+#"2*3#"/&%8*)G/%$(* @Q @ @ $%*A?@DC?*F3*N/%$(* @ @ @ (G+4J$*%+#$%%*B4"FG#<$#%8*4')2/(4'3*)1G'3$%*4'*+1$*24&4(*&$#@ @ )#$G%$*4'*+1$*"T4(G+4J$*%+#$%%*B4"FG#<$#%*)"')$'+#G+4"'* NR8>QO zyprazydonu Concentration of ziprasidoneMarker Control (without drug) Ziprasidone (drug)
n=10 n=10
139 ng/ml Tiole [nmol/mg białka]
Thiols [nmol/mg of protein] Mean valueŚrednia 2,802 2,821 p>0,05
SEM 0,101 0,095
250 ng/ml Tiole [nmol/mg białka]
Thiols [nmol/mg of protein] Mean valueŚrednia 2,802 2,850 p>0,05
SEM 0,101 0,086
TBARS [μmol/l]
TBARS [μmol/l] Mean valueŚrednia 1,618 2,064 p=3,9×10-4
SEM 0,056 0,110
TBARS dla stężenia zyprazydonu 139 ng/ml p<0,001 (praca w druku). TBARS for ziprasidone concentration 139 ng/ml p<0.001 (the study in print).
! ! 120 100 80 60 40 20 0 ZIP 139 ng/ml 101% p>0,05 ZIP 250 ng/ml 102% % Kontrola 100% Control 100%
@ @ @ @ @Q @ @ 2$</*A?@DC?*F3*N%+"%";G'.F* @ @
',-.#/$#/
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ng/ml Tiole 139 ng/mlThiols 139 ng/ml Thiols 250 ng/mlTiole 250 ng/ml
St ęż enie TBARS [ mol/l] TB ARS lev el [ $mol/l] St ęż enie w oln
ych tioli [nmol/mg bia
łka] Conc entr ation of fr ee thiols [nmol/mg of pr otein]
* Różnica (∆) względem kontroli. * Difference (∆) in relation to the control.
p=3,9×10-4*
244
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
[*+1$*%$)"'(*3$'$#G+4"'*G'+4&%.)1"+4)*[*4'*)"')$'+#G+4"'* @ @ @ *%+/(4$%*4'(4)G+$* +1G+*H4&#G%4("'$*4'*)"')$'+#G+4"'%*)"##$%&"'(4'3*+"*("%@ @ [*24&4(*&$#"T4(G+4"'*FG#<$#9 @ +4J$*%+#$%%*B4"FG#<$#%*G#$*J$#.*4F&"#+G'+*)24'4)G22.8*B$)G/%$* G'+4&%.)1"+4)%*4'*%)14H"&1#$'4)*&G+4$'+%*G#$*/%$(*)1#"'4@ @ @ @ @ 4')#$G%$*4'*&2G%FG*24&4(*&$#"T4(G+4"'8*+1$#$B.*$T14B4+4'3*
@ @ @ @ @ @ @ @ @ @ @ CQ,*QCE@QS=9 >??EW*D?,*>S@RR9 >??=W*DC,*RAC@RED9 @ +G#(4J$*(.%<4'$%4G9*L4"29*0%.)14G+#.*DEE?W*>A,*=R=@=RE9 @ 7)14H"&1#9*L/229*>??QW*R?,*E>R@ERQ9 >??RW*RS,*QR@=D9 )2"HG&4'$8*B/+*'"+*"2G'HG&4'$8*4'(/)$%*"T4(G+4J$*%+#$%%*4'*#G+* @ @ @ @ )1"+4)*(#/3%*J%9*1G2"&$#4("2*+"*&#"+$)+*0!D>*)$22%*G3G4'%+*600c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
